LSTU-01 - Antihistamines with 0% brain interference, from the science to the practical management
Tracks
Room D2
| Tuesday, September 2, 2025 |
| 13:00 - 14:00 |
Details
Supported by Opella
Speaker(s)
TBC
Programme:
| 13:00 – 13:03 | Welcome | |
| Welcome to the Symposium from the Opella Global Head of Science Hub | ||
| Dr Josephine Fubara, Opella, France | ||
| 13:03 – 13:06 | Introduction | |
| Present the objective of the symposium with the topics to cover and the respective speakers | ||
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | ||
| 13:06 – 13:11 | Allergy Rhinitis overview | |
| Brief introduction on Allergic Rhinitis condition and treatment options | ||
| TBC | ||
| 13:11 – 13:24 | Conference 1: Antihistamines with 0% brain interference: the clinical evidence | |
| Overview on the systematic review with a clinical perspective | ||
| Dr Ignacio Ansotegui, Hospital Quironsalud Bizkaia, Spain | ||
| 13:24 – 13:34 | Conference 2: Management of antihistamines with no brain penetration in the community pharmacy | |
| Review on Allergic Rhinitis and its management in the pharmacy settings, focusing on non-sedating antihistamines | ||
| Dr Ade Williams, Bedminster Pharmacy, UK | ||
| 13:34 – 13:44 | Conference 3: Fexofenadine, a truly non-sedating antihistamine | |
| Deep dive on fexofenadine properties and why it is a preferred choice | ||
| Dr Yorick Berger, France | ||
| 13:44 – 13:47 | Interactive Quiz | |
| Quiz to evaluate knowledge acquired by the audience | ||
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | ||
| 13:47 – 13:57 | Q&A | |
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | ||
| 13:57 – 14:00 | Closure and remarks | |
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia |
